Advanced strategies in immune Modulation of cancer Using Lipid-Based Nanoparticles

Purpose: Current cancer immunotherapy shows promise but fails across many tumour types, likely because single-pathway treatments cannot overcome the complex immunosuppressive tumour microenvironment (TME). Lipid-based nanoparticles (LNPs) may allow simultaneous, temporally coordinated delivery of multiple immune modulators to improve antitumor responses while reducing toxicity.

Hypothesis: If LNPs co-deliver tumour antigens, adjuvants, RNAi, cytokines, or checkpoint-modulating agents to antigen-presenting cells, tumour cells, or the TME, then multiple immune-evasion pathways can be targeted at once, enhancing innate and adaptive antitumor immunity and improving therapeutic efficacy.

Aims: Highlight recent advances in cancer immunotherapy using lipid-based nanoparticles as delivery vehicles. - Review LNP-based immunomodulation of antigen-presenting cells, especially dendritic cells and macrophages. - Review LNP-based targeting of tumour cells and the immunosuppressive TME. - Discuss sequential chemotherapy followed by immunotherapy and combination strategies. - Address ongoing challenges and potential opportunities in LNP immunotherapy.

Delivery system: Core platform: lipid-based nanoparticles, liposomes, and related lipid nanoparticles. - Examples cited: interbilayer-crosslinked multilamellar vesicles (ICMVs); RNA-lipoplexes (RNA-LPX); hyaluronan (HA)-coated LNPs; liposome-protamine-HA NPs; mannose-modified lipid-calcium-phosphate NPs; liposomal polymeric gels; cisplatin LNPs; CpG-encapsulated liposomes; coordination polymer LNPs. PLGA NPs are also discussed though not strictly lipid-based. - Payloads: tumour antigens, adjuvants (CpG, α-GalCer), siRNA (anti-CD47, anti-CCR2, anti-TGF-β, anti-IL-10), RNA-encoded antigens, IL-2, TGF-β inhibitor, chemotherapy (cisplatin, paclitaxel), and combinations with checkpoint blockade. - Targeting/functionalization: charge-based dendritic cell targeting, anti-DEC205 antibodies, HA–CD44/CD168 targeting, albumin-hitchhiking, CD47 “self” peptide, PEG, and polysaccharide coatings. - Goals: co-delivery to same cells, prolonged circulation, lymph node/TME targeting, reduced nonspecific immune activation, and RNAi delivery.

Approach: Review and synthesis of preclinical studies. Model systems across cited work include murine tumour models such as B16F10 melanoma, lymphoma, CT26, and MC38, with in vitro and in vivo immune assays. The review itself does not report primary experimental groups, n values, doses, or controls.

Key methods: Because this is a review, it does not generate primary headline data. The cited studies use techniques such as nanoparticle physicochemical characterisation, flow cytometry/immunophenotyping, siRNA-mediated knockdown, tumour growth and metastasis measurements, cytokine analysis, and immune cell infiltration assays.

Key results: Review-level findings include: - Co-delivery of antigen and adjuvant to the same antigen-presenting cell boosts immunogenicity; ICMVs elicited stronger antibody and CTL responses than simple liposomes. - RNA-LPX targeting dendritic cells induced strong effector and memory T-cell responses and IFN-dependent rejection of progressive tumours. - CCR2 siRNA LNPs reduced tumour-associated macrophages and tumour size in a mouse lymphoma model. - Anti-DEC205-targeted NPs co-delivering α-GalCer and ovalbumin triggered humoral and CTL responses and antitumor effects in B16F10 melanoma. - HA-coated LNPs carrying CD47 siRNA knocked down CD47, inhibited melanoma growth, and suppressed lung metastasis. - TGF-β siRNA plus vaccine increased tumour-infiltrating CD8+ T cells, decreased Tregs, and improved vaccine efficacy. - TGF-β inhibitor plus IL-2 in liposomal polymeric gels reduced tumour growth and increased immune response. - Albumin-hitchhiking vaccine combined with tumour-specific antibodies, IL-2, and anti-PD-1 eradicated large established tumours and induced protective CTL memory in murine models. - Sequential chemotherapy followed by immunotherapy showed synergistic effects against solid tumours. - Coordination polymer LNPs combining chemotherapy and photodynamic therapy, plus PD-L1 blockade, regressed primary and distant tumours in CT26 and MC38 models. - Surface functionalisation with PEG prolongs circulation but can activate complement and cause accelerated blood clearance; polysaccharides/HA and CD47 “self” peptide are alternatives to reduce immune recognition.

Interpretation: The authors argue that LNP-based immunotherapy enables targeted, temporal, and combinatorial delivery of immune modulators, potentially enhancing efficacy and reducing toxicity. They conclude that successful immunotherapy requires both innate and adaptive responses and that targeting multiple immune-evasion mechanisms is likely necessary, since single-agent approaches have limited clinical success.

Limitations: Review article, not primary data; no quantitative effect sizes. - Most cited studies are preclinical and use murine models. - Many models treat early-stage tumours before the immunosuppressive TME is fully developed. - Direct manipulation of tumour-resident lymphocytes has not yet been achieved. - Optimal combinations of nanoparticles and immune modulators for specific TMEs remain unclear. - Better murine models and computational biology approaches are needed. - Risks include autoimmunity and LNP-related immunogenicity, such as PEG-induced complement activation and accelerated blood clearance.